NeuroMetrix Receives FDA Breakthrough Device Designation for Treatment of Chronic Chemotherapy Induced Peripheral Neuropathy (CIPN) with its Wearable Neurostimulation Technology
January 18, 2022 09:00 ET
|
NeuroMetrix, Inc.
WOBURN, Mass., Jan. 18, 2022 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today announced that its Quell® technology has received Breakthrough Designation from the U.S. Food and Drug...
NeuroMetrix Reports Q3 2021 Financial Results
October 21, 2021 07:00 ET
|
NeuroMetrix, Inc.
WOBURN, Mass., Oct. 21, 2021 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported financial and business highlights for the quarter ended September 30, 2021. The Company is a leader...
NeuroMetrix Announces Peer-Reviewed Publication of a Randomized Controlled Trial of its Wearable Neurostimulation Technology for Treatment of Fibromyalgia
July 26, 2021 09:00 ET
|
NeuroMetrix, Inc.
WOBURN, Mass., July 26, 2021 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today announced a publication titled “Effects of Wearable Transcutaneous Electrical Nerve Stimulation on...
NeuroMetrix Reports Q2 2021 Financial Results
July 22, 2021 07:00 ET
|
NeuroMetrix, Inc.
WOBURN, Mass., July 22, 2021 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported financial and business highlights for the quarter ended June 30, 2021. The Company is a leader in...
NeuroMetrix Receives FDA Breakthrough Device Designation for Treatment of Fibromyalgia with its Wearable Neurostimulation Technology
July 20, 2021 09:00 ET
|
NeuroMetrix, Inc.
WOBURN, Mass., July 20, 2021 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today announced that its Quell® device has received Breakthrough Designation from the U.S. Food and Drug...
NeuroMetrix, Inc. Announces Date for Second Quarter 2021 Financial Results Conference Call
July 15, 2021 09:00 ET
|
NeuroMetrix, Inc.
WOBURN, Mass., July 15, 2021 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) announced today that it plans to issue its 2021 second quarter financial results before the opening of the market on...
NeuroMetrix Reports that Quell® Technology is to be Evaluated for Neuromyelitis Optica Spectrum Disorder (NMOSD) in a Randomized Controlled Trial
June 15, 2021 09:00 ET
|
NeuroMetrix, Inc.
WOBURN, Mass., June 15, 2021 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today announced that Quell technology will be used in a double-blinded, randomized, sham-controlled trial to...
NeuroMetrix Announces That Top-Line Results from a Randomized Controlled Trial of Quell® for Treatment of Fibromyalgia to be Presented at Two Upcoming Pain Medicine Conferences
June 09, 2021 08:00 ET
|
NeuroMetrix, Inc.
WOBURN, Mass., June 09, 2021 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported that top-line results from a randomized controlled trial of Quell in patients with fibromyalgia will...
NeuroMetrix Reports Q1 2021 Financial Results
April 22, 2021 07:00 ET
|
NeuroMetrix, Inc.
WOBURN, Mass., April 22, 2021 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported financial and business highlights for the quarter ended March 31, 2021. The Company is a leader in...
NeuroMetrix, Inc. Announces Date for First Quarter 2021 Financial Results Conference Call
April 15, 2021 13:00 ET
|
NeuroMetrix, Inc.
WOBURN, Mass., April 15, 2021 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) announced today that it plans to issue its 2021 first quarter financial results before the opening of the market on...